Axsome Therapeutics (AXSM) Operating Expenses (2015 - 2026)

Axsome Therapeutics has reported Operating Expenses for 12 years, with the latest figure at $254.6 million in Q1 2026.

• Quarterly Operating Expenses rose 42.65% year-over-year to $254.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $881.4 million (up 25.48% YoY) and the FY2025 annual result came in at $805.3 million, up 20.86% from the prior year.
• Operating Expenses improved to $254.6 million in Q1 2026 per AXSM's latest filing, from $223.0 million in the prior quarter.
• Over five years, Operating Expenses peaked at $254.6 million in Q1 2026 and troughed at $38.3 million in Q1 2022.
• A 5-year average of $144.6 million and a median of $165.2 million in 2024 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2023 and 2024: Operating Expenses jumped 163.65% in 2023, then climbed 12.71% in 2024.
• Over 5 years, Operating Expenses stood at $84.3 million in 2022, then soared by 101.45% to $169.8 million in 2023, then rose by 12.71% to $191.4 million in 2024, then advanced by 16.5% to $223.0 million in 2025, then increased by 14.17% to $254.6 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $254.6 million, $223.0 million, and $217.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.